肺高血圧に対する家庭での運動プログラムとセンターでの運動プログラムの有効性と安全性:メタ解析による体系的レビュー
Indyanara C Ribeiro1,2,3, Sofia M Sieczkowska1,2,3, Renata Jashchenko4
1Applied Physiology and Nutrition Research Group, School of Physical Education and Sport, University of São Paulo (USP), São Paulo, Brazil.
まとめ
自宅での運動トレーニングは肺高血圧の患者の治療結果を改善し,センターベースのプログラムに有効な代替手段を提供します. 比較可能な結果があり,重度の有害事象は報告されていません.
科学分野:
- 心臓病科
- 肺科
- リハビリテーション医学
背景:
- 肺高血圧 (PH) は運動能力と生活の質を著しく損なう.
- リハビリテーションセンターへのアクセスが 制限されているため 運動訓練は 制限されています
- 自宅での運動は 入手可能で費用対効果の高い選択肢ですが 効果と安全性については 検討が必要です
研究 の 目的:
- 肺高血圧患者の自宅での運動介入の有効性と安全性を体系的に検討し,メタ分析する.
- 家庭での運動の成果を 非活動的な対照群と センターベースのプログラムと比較する
- 運動訓練に伴う有害事象の評価と特定
主な方法:
- 19件の研究の体系的レビューとメタ解析.
- PH患者における単独およびハイブリッドの家庭での運動介入を評価した研究を含める.
- 安全性,運動能力,心臓呼吸器効果,機能的クラス,およびアデバーンスの評価
主要な成果:
- 家庭での運動は,対照群と比較して,歩行距離6分,酸素吸収のピーク,および生活の質を大幅に改善しました.
- 改善はセンターベースの介入と比べられます.
- 重度の有害事象は報告されなかったが,自己モニタリングデータは限られていた.
結論:
- 自宅での運動介入は 肺高血圧のセンターベースのプログラムに 実行可能で効果的な代替手段です
- 比較可能な臨床結果の改善は生存可能性を示唆するが,包括的な安全性評価のために自己モニタリングに関するさらなる研究が必要である.
関連する概念動画
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
317
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
317
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
253
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
247
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
247
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
01:30Pulmonary Hypertension: Classification and Pathogenesis
284
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
284
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27